Brokers Offer Predictions for Novavax FY2027 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Equities research analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Novavax in a note issued to investors on Thursday, March 20th. Zacks Research analyst S. Ganoria expects that the biopharmaceutical company will post earnings of $0.54 per share for the year. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same period in the previous year, the company posted ($1.44) earnings per share.

Several other analysts have also commented on NVAX. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. BTIG Research initiated coverage on Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 price target for the company. Finally, TD Cowen upgraded shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $18.00.

Novavax Stock Down 1.7 %

Shares of NVAX opened at $7.56 on Monday. The company has a 50 day moving average of $8.21 and a two-hundred day moving average of $9.44. Novavax has a twelve month low of $3.81 and a twelve month high of $23.86. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -3.35, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92.

Insider Buying and Selling

In related news, Director James F. Young sold 5,400 shares of Novavax stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the sale, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.00% of the stock is owned by insiders.

Institutional Trading of Novavax

A number of institutional investors have recently made changes to their positions in NVAX. Vanguard Group Inc. lifted its holdings in Novavax by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company’s stock valued at $126,439,000 after purchasing an additional 296,181 shares in the last quarter. Shah Capital Management lifted its stake in shares of Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after buying an additional 1,333,305 shares in the last quarter. State Street Corp grew its stake in Novavax by 26.7% during the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after acquiring an additional 1,621,772 shares in the last quarter. Sanofi acquired a new stake in Novavax in the 4th quarter valued at about $55,319,000. Finally, Geode Capital Management LLC lifted its stake in Novavax by 4.4% in the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company’s stock worth $29,415,000 after purchasing an additional 155,206 shares in the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.